Key Takeaways
- BIOSTAR PHARM-B to issue 25 million new shares at HKD 4 each.
- Net proceeds of approximately HKD100 million to fund ADC development.
- Baiyang Pharmaceutical's stake to increase from 1.14% to 7.49%.
Back
Back
Biostar Pharm-B to Raise HKD100 Million for ADC Development
BIOSTAR PHARM-B (02563.HK) will raise approximately HKD100 million in net proceeds through a strategic share issuance to deepen its work on antibody-drug conjugate (ADC) products.
The company announced it will issue 25 million new shares to Baiyang Health Industry, a wholly-owned subsidiary of its strategic partner Baiyang Pharmaceutical (30105.SZ).
The new shares were priced at HKD 4 per share, a discount of 11.11 percent to the closing price on the day of the announcement. Upon completion of the transaction, Baiyang Pharmaceutical's stake in BIOSTAR PHARM-B will increase significantly, moving from 1.14 percent to 7.49 percent.
This capital injection is earmarked for the development of the company's ADC products and platforms. The funds will also be used for deepening commercialization cooperation, launching new projects, and for general working capital. The move strengthens the strategic partnership between the two companies and provides a substantial boost to BIOSTAR's research and development capabilities in the high-growth ADC sector.
The strengthened alliance with Baiyang Pharmaceutical, a major player in the Chinese pharmaceutical market, is expected to enhance BIOSTAR's commercialization pathways and market access for its pipeline products. For investors, this strategic financing and deepened partnership signal a clear focus on advancing the company's ADC technology. The market will be watching for pipeline updates and progress on the commercialization front following this capital raise.
This article is for informational purposes only and does not constitute investment advice.
